Latest news and press releases about Reviva Pharmaceuticals Holdings, Inc. (RVPH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Price
| Price | $0.49 |
| Market Cap | $6M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | 7.54 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -64.39% |
| Return on Invested Capital | -17.05% |
| Return on Assets | -11.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · FGEN
Explore sector: Healthcare · Biotechnology
More sections of RVPH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks